Polivy

Disease:

Approved for the treatment of relapse or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies.

About Polivy:

Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B-cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to CD79b and destroys these B-cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells.

About DLBCL:

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma (NHL), accounting for about one in three cases of NHL. DLBCL is an aggressive (fast-growing) type of NHL, which is generally responsive to treatment in the frontline. However, as many as 40 percent of patients will relapse, at which time salvage therapy options are limited and survival is short.

What Makes it Unique:

After a decade of development, Polivy provides a novel treatment option for patients battling this aggressive lymphoma.  Polivy received an accelerated approval based on the results from the Phase Ib/II study, which was the first and only randomized pivotal clinical trial to show higher response rates over BR, a commonly used regimen, in people with R/R DLBCL who are ineligible for a hematopoietic stem cell transplant.